Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders
- PMID: 23736534
- DOI: 10.1093/eurjhf/hft088
Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders
Abstract
Aims: MicroRNAs (miRNAs) play an important role in the pathogenesis of structural alterations of the failing heart through their ability to regulate negatively the expression levels of genes that govern the process of adaptive and maladaptive cardiac remodelling. We studied whether LV reverse remodelling after CRT was associated with changes of circulating miRNAs in patients with heart failure (HF) and dyssynchrony.
Methods and results: A prospective, non-randomized self-control trial was performed in 81 patients with HF eligible for CRT. At baseline, to select the HF miRNA profile, we evaluated the expression of 84 miRNAs (implicated in the pathogenesis of structural alterations of the failing heart) in three groups of patients: healthy subjects (healthy group, n = 15); patients with HF (HF group, n = 81); and patients without HF matched for age, sex, and concomitant disease with HF patients (control group, n = 60). At 12 months, the selected miRNA profile was evaluated in plasma from responder (n = 55) and non-responder HF patients (n = 26) to CRT. In the test cohort, the HF patients were characterized by lower expression of 48 miRNAs (all P < 0.04) as compared with healthy subjects. In the validation cohort, the HF patients were characterized by lower expression of 24 miRNAs (all P < 0.03) as compared with control patients. At 12 months, 55 patients (68%) were considered responders and 26 non-responders to CRT (32%). Responders showed an increase in expression of 19 miRNAs (all P < 0.03) compared with baseline expression, whereas in the non-responders we observed an increase of six miRNAs (all P < 0.05) compared with baseline expression. At follow-up, miRNAs were differentially expressed between responders and non-responders. The responders were characterized by higher expression of five miRNAs (miRNA-26b-5p, miRNA-145-5p, miRNA-92a-3p, miRNA-30e-5p, and miRNA-29a-3p; P < 0.01 for all) as compared with non-responders.
Conclusions: In responders, reverse remodelling is associated with favourable changes in miRNAs that regulate cardiac fibrosis, apoptosis, and hypertrophy.
Keywords: Cardiac resynchronization therapy; Heart failure; MicroRNAs.
Similar articles
-
Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure.Int J Cardiol. 2011 Dec 15;153(3):306-10. doi: 10.1016/j.ijcard.2010.08.048. Epub 2010 Sep 21. Int J Cardiol. 2011. PMID: 20863582
-
Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders.J Am Coll Cardiol. 2008 Jan 15;51(2):129-36. doi: 10.1016/j.jacc.2007.07.087. J Am Coll Cardiol. 2008. PMID: 18191736
-
Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.Eur J Heart Fail. 2012 Jan;14(1):74-81. doi: 10.1093/eurjhf/hfr151. Epub 2011 Nov 16. Eur J Heart Fail. 2012. PMID: 22089058 Clinical Trial.
-
Functional role of miRNA in cardiac resynchronization therapy.Pharmacogenomics. 2014 Jun;15(8):1159-68. doi: 10.2217/pgs.14.76. Pharmacogenomics. 2014. PMID: 25084208 Review.
-
Role of microRNAs in cardiac remodeling and heart failure.Cardiovasc Drugs Ther. 2011 Apr;25(2):171-82. doi: 10.1007/s10557-011-6289-5. Cardiovasc Drugs Ther. 2011. PMID: 21431305 Review.
Cited by
-
miR Profile of Chronic Right Ventricular Pacing: a Pilot Study in Children with Congenital Complete Atrioventricular Block.J Cardiovasc Transl Res. 2023 Apr;16(2):287-299. doi: 10.1007/s12265-022-10318-w. Epub 2022 Sep 19. J Cardiovasc Transl Res. 2023. PMID: 36121621 Free PMC article.
-
Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control.Front Physiol. 2018 Oct 30;9:1514. doi: 10.3389/fphys.2018.01514. eCollection 2018. Front Physiol. 2018. PMID: 30425649 Free PMC article. Review.
-
Mesenchymal stem cell-derived exosomes: a possible therapeutic strategy for repairing heart injuries.Front Cell Dev Biol. 2023 Jun 30;11:1093113. doi: 10.3389/fcell.2023.1093113. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37457298 Free PMC article. Review.
-
Combined flow-based imaging assessment of optimal cardiac resynchronization therapy pacing vector: a case report.J Med Case Rep. 2019 May 25;13(1):161. doi: 10.1186/s13256-019-2048-1. J Med Case Rep. 2019. PMID: 31126329 Free PMC article.
-
Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome.Front Physiol. 2018 Jun 26;9:758. doi: 10.3389/fphys.2018.00758. eCollection 2018. Front Physiol. 2018. PMID: 29997521 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous